These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 22050449)

  • 21. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
    Pace F; Pace M
    Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.
    Kung YM; Hsu WH; Wu MC; Wang JW; Liu CJ; Su YC; Kuo CH; Kuo FC; Wu DC; Wang YK
    Dig Dis Sci; 2017 Dec; 62(12):3298-3316. PubMed ID: 29110162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial.
    Ostovaneh MR; Saeidi B; Hajifathalian K; Farrokhi-Khajeh-Pasha Y; Fotouhi A; Mirbagheri SS; Emami H; Barzin G; Mirbagheri SA
    Neurogastroenterol Motil; 2014 May; 26(5):670-8. PubMed ID: 24533896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes.
    Dettmar PW; Sykes J; Little SL; Bryan J
    Int J Clin Pract; 2006 Mar; 60(3):275-83. PubMed ID: 16494641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
    Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
    World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
    Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
    Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M; Manabe N; Haruma K
    Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
    Barberio B; Visaggi P; Savarino E; de Bortoli N; Black CJ; Ford AC
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14469. PubMed ID: 36153790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Study of Alginate and Omeprazole in Symptomatic Treatment of Non-erosive Gastroesophageal Reflux Disease.
    Saifullah AM; Ahmed F; Shil BC; Banik RK; Saha SK; Chowdhury M; Haque A; Alam MS; Akhter A
    Mymensingh Med J; 2018 Oct; 27(4):771-775. PubMed ID: 30487493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
    Pouchain D; Bigard MA; Liard F; Childs M; Decaudin A; McVey D
    BMC Gastroenterol; 2012 Feb; 12():18. PubMed ID: 22361121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
    Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-center retrospective study on epidemiological and Traditional Chinese Medicine syndrome characteristics of 21010 patients with reflux/heartburn symptoms.
    Yanping T; Peicai LI; Xi L; Lei L; Yanxia G; Xiaodong W; Lina L; Li Y
    J Tradit Chin Med; 2023 Jun; 43(3):574-581. PubMed ID: 37147760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
    Bate CM; Green JR; Axon AT; Murray FE; Tildesley G; Emmas CE; Taylor MD
    Aliment Pharmacol Ther; 1997 Aug; 11(4):755-63. PubMed ID: 9305486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
    Galmiche JP; Barthelemy P; Hamelin B
    Aliment Pharmacol Ther; 1997 Aug; 11(4):765-73. PubMed ID: 9305487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.